Barclays’s Gilead Sciences GILD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$35.4M Sell
254,100
-30,000
-11% -$4.2M 0.01% 855
2025
Q4
$34.9M Hold
284,100
0.01% 948
2025
Q3
$31.5M Sell
284,100
-49,400
-15% -$5.62M 0.01% 991
2025
Q2
$37M Buy
333,500
+200,900
+152% +$21.4M 0.01% 839
2025
Q1
$14.9M Buy
132,600
+5,000
+4% +$516K ﹤0.01% 1173
2024
Q4
$11.8M Hold
127,600
﹤0.01% 1454
2024
Q3
$10.7M Buy
+127,600
New +$9.74M ﹤0.01% 1442
2024
Q2
Sell
-126,400
Closed -$9.26M 5034
2024
Q1
$9.26M Sell
126,400
-75,600
-37% -$5.81M ﹤0.01% 1449
2023
Q4
$16.4M Sell
202,000
-128,600
-39% -$10M 0.01% 1161
2023
Q3
$24.8M Sell
330,600
-117,600
-26% -$9.05M 0.02% 695
2023
Q2
$34.5M Buy
448,200
+200,600
+81% +$16M 0.02% 569
2023
Q1
$20.5M Buy
+247,600
New +$20.5M 0.01% 830
2022
Q1
Sell
-1,001,400
Closed -$72.7M 5196
2021
Q4
$72.7M Buy
1,001,400
+486,400
+94% +$33.5M 0.03% 445
2021
Q3
$36M Buy
515,000
+170,000
+49% +$11.9M 0.02% 658
2021
Q2
$23.8M Buy
345,000
+315,000
+1,050% +$21M 0.01% 806
2021
Q1
$1.94M Sell
30,000
-78,200
-72% -$5.04M ﹤0.01% 2301
2020
Q4
$6.3M Hold
108,200
﹤0.01% 1383
2020
Q3
$6.84M Sell
108,200
-1,600
-1% -$111K ﹤0.01% 1219
2020
Q2
$8.45M Sell
109,800
-677,500
-86% -$51.9M 0.01% 1057
2020
Q1
$58.9M Buy
787,300
+189,900
+32% +$13.1M 0.05% 275
2019
Q4
$38.8M Buy
597,400
+32,600
+6% +$2.12M 0.02% 613
2019
Q3
$35.8M Buy
564,800
+162,100
+40% +$10.6M 0.02% 584
2019
Q2
$27.2M Sell
402,700
-143,600
-26% -$9.45M 0.02% 760
2019
Q1
$35.5M Sell
546,300
-107,600
-16% -$7.15M 0.02% 558
2018
Q4
$40.9M Sell
653,900
-182,500
-22% -$12.8M 0.03% 450
2018
Q3
$64.6M Buy
836,400
+165,800
+25% +$12.5M 0.04% 320
2018
Q2
$47.5M Buy
670,600
+126,700
+23% +$8.95M 0.04% 373
2018
Q1
$41M Sell
543,900
-548,500
-50% -$43.6M 0.03% 504
2017
Q4
$78.3M Buy
1,092,400
+139,600
+15% +$10.6M 0.06% 249
2017
Q3
$77.2M Buy
952,800
+630,200
+195% +$48.2M 0.08% 201
2017
Q2
$22.8M Sell
322,600
-513,000
-61% -$34.1M 0.02% 547
2017
Q1
$56.8M Sell
835,600
-332,700
-28% -$23.4M 0.06% 221
2016
Q4
$83.7M Sell
1,168,300
-68,600
-6% -$5.1M 0.09% 172
2016
Q3
$97.9M Buy
1,236,900
+233,100
+23% +$18.9M 0.11% 141
2016
Q2
$83.7M Buy
1,003,800
+366,400
+57% +$32.5M 0.11% 144
2016
Q1
$58M Sell
637,400
-1,094,900
-63% -$98.7M 0.09% 182
2015
Q4
$175M Sell
1,732,300
-1,821,600
-51% -$190M 0.21% 78
2015
Q3
$348M Buy
3,553,900
+248,200
+8% +$27.6M 0.42% 27
2015
Q2
$387M Sell
3,305,700
-1,246,100
-27% -$136M 0.43% 23
2015
Q1
$446M Buy
4,551,800
+253,600
+6% +$25.8M 0.51% 18
2014
Q4
$404M Buy
4,298,200
+149,800
+4% +$15.5M 0.39% 27
2014
Q3
$440M Buy
4,148,400
+976,900
+31% +$95.7M 0.42% 28
2014
Q2
$260M Sell
3,171,500
-412,400
-12% -$32.1M 0.28% 46
2014
Q1
$251M Buy
3,583,900
+3,113,300
+662% +$244M 0.28% 48
2013
Q4
$35.3M Sell
470,600
-730,200
-61% -$50.8M 0.04% 480
2013
Q3
$74.4M Buy
1,200,800
+934,800
+351% +$55.9M 0.09% 189
2013
Q2
$13.6M Buy
+266,000
New +$13.9M 0.02% 862

Other funds holding GILD

Barclays's GILD Position: Q1 2026 in Review

Barclays reduced its Gilead Sciences (GILD) stake by 42% in Q1 2026, selling an estimated $537M and leaving 5,282,196 shares worth $736M. The position accounts for 0.18% of the portfolio, ranked #85.

Barclays first reported a position in GILD in Q2 2013 and has held it in 52 quarters since. The position peaked at $1.12B in Q4 2025. 2,309 funds tracked by Wall St. Rank hold GILD as of Q1 2026.

  • Barclays held 5,282,196 shares of Gilead Sciences worth $736M as of Q1 2026.
  • Barclays sold 3,833,287 Gilead Sciences shares in Q1 2026, an estimated $537M.
  • Gilead Sciences made up 0.18% of Barclays's portfolio in Q1 2026, its #85 holding.
  • Barclays first reported a position in Gilead Sciences in Q2 2013 and has held it in 52 quarters since.
  • Barclays's Gilead Sciences position peaked at $1.12B in Q4 2025.
  • 2,309 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.